论文部分内容阅读
作者评价了1975年到1986年1月间欧洲骨髓移植协作组严重再障登记处登记的468例严重再障(SAA)病人.这些病人未经骨髓移植,而用免疫抑制剂(IS,96%病人接受ATG)治疗.接受治疗时,中位数年龄是23岁(1-73岁),男性病人占59%,原发性再障占69%.468例病人中,245例用IS治疗后随访不到2年,其中166例死亡,71例仍存活,8例失去联系;223例生存期大于或等于2年(LTS,即长期生存者),191例仍存活,21例2年后死亡,11例失去联系.
The authors evaluated 468 patients with severe aplastic anemia (SAA) who were enrolled in the European Society for Marrow Bone Marrow Grafting from 1975 to January 1986. These patients were treated with an immunosuppressant (IS, 96% Patients were treated with ATG.) Median age was 23 years old (1-73 years) with 59% of males and 69% of patients with primary aplastic anemia. Of the 468 patients, 245 were treated with IS Of these, 166 died, 71 survived, and 8 lost contact; 223 survived for more than or equal to 2 years (LTS, long-term survival), 191 remained alive and 21 died two years later , 11 cases lost contact.